Cargando…

Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy

BACKGROUND: Nanoparticle based delivery of anticancer drugs have been widely investigated. However, a very important process for Research & Development in any pharmaceutical industry is scaling nanoparticle formulation techniques so as to produce large batches for preclinical and clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranjan, Amalendu P, Mukerjee, Anindita, Helson, Lawrence, Vishwanatha, Jamboor K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497871/
https://www.ncbi.nlm.nih.gov/pubmed/22937885
http://dx.doi.org/10.1186/1477-3155-10-38
_version_ 1782249768578187264
author Ranjan, Amalendu P
Mukerjee, Anindita
Helson, Lawrence
Vishwanatha, Jamboor K
author_facet Ranjan, Amalendu P
Mukerjee, Anindita
Helson, Lawrence
Vishwanatha, Jamboor K
author_sort Ranjan, Amalendu P
collection PubMed
description BACKGROUND: Nanoparticle based delivery of anticancer drugs have been widely investigated. However, a very important process for Research & Development in any pharmaceutical industry is scaling nanoparticle formulation techniques so as to produce large batches for preclinical and clinical trials. This process is not only critical but also difficult as it involves various formulation parameters to be modulated all in the same process. METHODS: In our present study, we formulated curcumin loaded poly (lactic acid-co-glycolic acid) nanoparticles (PLGA-CURC). This improved the bioavailability of curcumin, a potent natural anticancer drug, making it suitable for cancer therapy. Post formulation, we optimized our process by Reponse Surface Methodology (RSM) using Central Composite Design (CCD) and scaled up the formulation process in four stages with final scale-up process yielding 5 g of curcumin loaded nanoparticles within the laboratory setup. The nanoparticles formed after scale-up process were characterized for particle size, drug loading and encapsulation efficiency, surface morphology, in vitro release kinetics and pharmacokinetics. Stability analysis and gamma sterilization were also carried out. RESULTS: Results revealed that that process scale-up is being mastered for elaboration to 5 g level. The mean nanoparticle size of the scaled up batch was found to be 158.5 ± 9.8 nm and the drug loading was determined to be 10.32 ± 1.4%. The in vitro release study illustrated a slow sustained release corresponding to 75% drug over a period of 10 days. The pharmacokinetic profile of PLGA-CURC in rats following i.v. administration showed two compartmental model with the area under the curve (AUC(0-∞)) being 6.139 mg/L h. Gamma sterilization showed no significant change in the particle size or drug loading of the nanoparticles. Stability analysis revealed long term physiochemical stability of the PLGA-CURC formulation. CONCLUSIONS: A successful effort towards formulating, optimizing and scaling up PLGA-CURC by using Solid-Oil/Water emulsion technique was demonstrated. The process used CCD-RSM for optimization and further scaled up to produce 5 g of PLGA-CURC with almost similar physicochemical characteristics as that of the primary formulated batch.
format Online
Article
Text
id pubmed-3497871
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34978712012-11-20 Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy Ranjan, Amalendu P Mukerjee, Anindita Helson, Lawrence Vishwanatha, Jamboor K J Nanobiotechnology Research BACKGROUND: Nanoparticle based delivery of anticancer drugs have been widely investigated. However, a very important process for Research & Development in any pharmaceutical industry is scaling nanoparticle formulation techniques so as to produce large batches for preclinical and clinical trials. This process is not only critical but also difficult as it involves various formulation parameters to be modulated all in the same process. METHODS: In our present study, we formulated curcumin loaded poly (lactic acid-co-glycolic acid) nanoparticles (PLGA-CURC). This improved the bioavailability of curcumin, a potent natural anticancer drug, making it suitable for cancer therapy. Post formulation, we optimized our process by Reponse Surface Methodology (RSM) using Central Composite Design (CCD) and scaled up the formulation process in four stages with final scale-up process yielding 5 g of curcumin loaded nanoparticles within the laboratory setup. The nanoparticles formed after scale-up process were characterized for particle size, drug loading and encapsulation efficiency, surface morphology, in vitro release kinetics and pharmacokinetics. Stability analysis and gamma sterilization were also carried out. RESULTS: Results revealed that that process scale-up is being mastered for elaboration to 5 g level. The mean nanoparticle size of the scaled up batch was found to be 158.5 ± 9.8 nm and the drug loading was determined to be 10.32 ± 1.4%. The in vitro release study illustrated a slow sustained release corresponding to 75% drug over a period of 10 days. The pharmacokinetic profile of PLGA-CURC in rats following i.v. administration showed two compartmental model with the area under the curve (AUC(0-∞)) being 6.139 mg/L h. Gamma sterilization showed no significant change in the particle size or drug loading of the nanoparticles. Stability analysis revealed long term physiochemical stability of the PLGA-CURC formulation. CONCLUSIONS: A successful effort towards formulating, optimizing and scaling up PLGA-CURC by using Solid-Oil/Water emulsion technique was demonstrated. The process used CCD-RSM for optimization and further scaled up to produce 5 g of PLGA-CURC with almost similar physicochemical characteristics as that of the primary formulated batch. BioMed Central 2012-08-31 /pmc/articles/PMC3497871/ /pubmed/22937885 http://dx.doi.org/10.1186/1477-3155-10-38 Text en Copyright ©2012 Ranjan et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ranjan, Amalendu P
Mukerjee, Anindita
Helson, Lawrence
Vishwanatha, Jamboor K
Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy
title Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy
title_full Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy
title_fullStr Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy
title_full_unstemmed Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy
title_short Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy
title_sort scale up, optimization and stability analysis of curcumin c3 complex-loaded nanoparticles for cancer therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497871/
https://www.ncbi.nlm.nih.gov/pubmed/22937885
http://dx.doi.org/10.1186/1477-3155-10-38
work_keys_str_mv AT ranjanamalendup scaleupoptimizationandstabilityanalysisofcurcuminc3complexloadednanoparticlesforcancertherapy
AT mukerjeeanindita scaleupoptimizationandstabilityanalysisofcurcuminc3complexloadednanoparticlesforcancertherapy
AT helsonlawrence scaleupoptimizationandstabilityanalysisofcurcuminc3complexloadednanoparticlesforcancertherapy
AT vishwanathajamboork scaleupoptimizationandstabilityanalysisofcurcuminc3complexloadednanoparticlesforcancertherapy